(window["webpackJsonp"]=window["webpackJsonp"]||[]).push([["chunk-dca937f8"],{"0559":function(e,i,n){},1583:function(e,i,n){},2241:function(e,i,n){"use strict";var a=function(){var e=this,i=e.$createElement,n=e._self._c||i;return n("div",{staticClass:"logos"},["jcarh125"===e.$route.params.id?n("p",{staticClass:"footnote"},[n("sup",[e._v("a")]),e._v(" Being developed by a company.\n  ")]):e._e()])},t=[],o={name:"Logo"},m=o,s=(n("4adf"),n("2877")),r=Object(s["a"])(m,a,t,!1,null,"0887eda8",null);i["a"]=r.exports},"49d2":function(e,i,n){"use strict";var a=n("1583"),t=n.n(a);t.a},"4adf":function(e,i,n){"use strict";var a=n("0559"),t=n.n(a);t.a},"4e57":function(e){e.exports={areas:{myeloma:{id:"myeloma",title:"Lorem Ipsum",therapies:["bb2121","bb21217","jcarh125"]},lymphoma:{id:"lymphoma",title:"Dolor Sit Amet",therapies:["liso-cel"]}},therapy:{"liso-cel":{buttonLabel:"Consectetur Adipiscing Elit",checkboxLabel:"Consectetur Adipiscing Elit",heading:"Consectetur Adipiscing Elit",subheading:"Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.<sup>4</sup>",sidebarTitle:"Sed-Do",videos:[{id:"ch1",src:"video6.mp4",ref:"liso1",title:"Duis aute irure",thumb:"thumbnail6.jpg"},{id:"ch2",src:"video7.mp4",ref:"liso2",title:"Dolor In Reprehenderit",thumb:"thumbnail7.jpg"},{id:"ch3",src:"video8.mp4",ref:"liso3",title:"In Voluptate Velit Esse Cillum",thumb:"thumbnail8.jpg"},{id:"ch4",src:"video9.mp4",ref:"liso4",title:"Dolore Eu Fugiat Nulla Pariatur",thumb:"thumbnail9.jpg"},{id:"ch5",src:"video10.mp4",ref:"liso5",title:"Excepteur Sint Occaecat Cupidatat",thumb:"thumbnail10.jpg"}],trials:[{id:"world",tab:"NON PROIDENT",heading:"Sunt in Culpa Qui Officia Deserunt Mollit Anim id est Laborum",trialCode:"ABC-123 (NON PROIDENT)",subheading:"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.",phase:"2",status:"Nemo",primaryEndpts:"ENIM",govId:"ABC12345678",contact:"Ipsam Voluptatem Quia Voluptas Sit (place@holder.com)",secondaryEndpts:"aspernatur aut odit aut fugit",schematic:"transcend-world.svg",footnotes:["<sup>a</sup> On underlying CLL in patients with Richter’s transformation. <sup>b</sup> NHL is defined as patients with DLBCL NOS (de novo or tFL), high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology and FL3B per WHO 2016 classification. <sup>c</sup> DHL/THL high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements."],abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"CLL",definition:"chronic lymphocytic leukemia"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"DLBCL",definition:"diffuse large B-cell lymphoma"},{name:"DOR",definition:"duration of response"},{name:"DHL",definition:"double hit lymphoma"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"EFS",definition:"event-free survival"},{name:"FL",definition:"follicular lymphoma"},{name:"FL3B",definition:"follicular lymphoma grade 3B"},{name:"HRQoL",definition:"health-related quality of life"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow-up"},{name:"NHL",definition:"non-Hodgkin lymphoma"},{name:"NOS",definition:"not otherwise specified"},{name:"NTE",definition:"non-transplant eligible"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PCNSL",definition:"primary central nervous system lymphoma"},{name:"PET",definition:"positron emission tomography"},{name:"PFS",definition:"progression-free survival"},{name:"PK",definition:"pharmacokinetics"},{name:"PRO",definition:"patient-reported outcome"},{name:"R/R",definition:"relapsed/refractory"},{name:"THL",definition:"triple hit lymphoma"},{name:"tFL",definition:"transformed follicular lymphoma"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"},{name:"WHO",definition:"World Health Organization"}],accessData:"https://google.com/. Accessed XXX 30, 2019."},{id:"nhl001",tab:"QUIS AUTEM VEL",heading:"Eum Iure Reprehenderit Qui in ea Voluptate",trialCode:"QUIS AUTEM VEL",subheading:"Velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur.",phase:"1; seamless",status:"Nemo",primaryEndpts:"At, Vero, Eos",govId:"DEF23456789",contact:"Et Accusamus et Iusto (place@holder.com)",secondaryEndpts:"ducimus qui blanditiis",schematic:"transcend-nhl.svg",abbreviations:[{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"DHL",definition:"double hit lymphoma"},{name:"DLBCL",definition:"diffuse large B-cell lymphoma"},{name:"DOR",definition:"duration of response"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"FL",definition:"follicular lymphoma"},{name:"HRQoL",definition:"health-related quality of life"},{name:"HSCT",definition:"hematopoietic stem cell transplantation"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow-up"},{name:"MCL",definition:"mantle cell lymphoma"},{name:"NHL",definition:"non-Hodgkin lymphoma"},{name:"NOS",definition:"not otherwise specified"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PET",definition:"positron emission tomography"},{name:"PFS",definition:"progression-free survival"},{name:"PK",definition:"pharmacokinetics"},{name:"PMBCL",definition:"primary mediastinal large B-cell lymphoma"},{name:"R/R",definition:"relapsed/refractory"},{name:"TEAE",definition:"treatment-emergent adverse event"},{name:"tDLBCL",definition:"transformed diffuse large B-cell lymphoma"},{name:"THL",definition:"triple hit lymphoma"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"}],accessData:"https://google.com/. Accessed XXX 30, 2019."},{id:"nhl006",tab:"PRAESENTIUM VOLUPTATUM DELENITI",heading:"Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",trialCode:"PRAESENTIUM VOLUPTATUM DELENITI",subheading:"Atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga.",phase:"2",status:"Nemo",primaryEndpts:"FCD",govId:"HIJ34567890",contact:"Et Harum Quidem (place@holder.com)",secondaryEndpts:"Arerum facilis est et expedita distinctio",schematic:"transcend-pilot.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"DHL",definition:"double hit lymphoma"},{name:"DLBCL",definition:"diffuse large B-cell lymphoma"},{name:"DOR",definition:"duration of response"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"EFS",definition:"event-free survival"},{name:"FL",definition:"follicular lymphoma"},{name:"HRQoL",definition:"health-related quality of life"},{name:"HSCT",definition:"hematopoietic stem cell transplantation"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow-up"},{name:"NHL",definition:"non-Hodgkin lymphoma"},{name:"NOS",definition:"not otherwise specified"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PFS",definition:"progression-free survival"},{name:"PK",definition:"pharmacokinetics"},{name:"R/R",definition:"relapsed/refractory"},{name:"TFL",definition:"transformed follicular lymphoma"},{name:"THL",definition:"triple hit lymphoma"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"}],accessData:"https://google.com. Accessed XXX 30, 2019."},{id:"cll004",tab:"",heading:"Relapsed or Refractory B-Cell CLL or SLL",trialCode:"Nam libero",subheading:"Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae.",phase:"1/2",status:"REVO",primaryEndpts:"Itaque earum rerum hic tenetur a sapiente delectus",govId:"KLM45678901",contact:"Ut Aut Resapiente (place@holder.com)",secondaryEndpts:"Voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat.",schematic:"transcend-cll.svg",footnotes:["<sup>a</sup> Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."],abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"CLL",definition:"chronic lymphocytic leukemia"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"EFS",definition:"event-free survival"},{name:"FL",definition:"follicular lymphoma"},{name:"HRQoL",definition:"health-related quality of life"},{name:"IV",definition:"intravenous"},{name:"iwCLL",definition:"International Workshop on Chronic Lymphocytic Leukemia"},{name:"LTFU",definition:"long-term follow-up"},{name:"MRD",definition:"minimal residual disease"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PFS",definition:"progression-free survival"},{name:"PK",definition:"pharmacokinetics"},{name:"RP2D",definition:"recommended phase 2 dose"},{name:"R/R",definition:"relapsed/refractory"},{name:"SLL",definition:"small lymphocytic lymphoma"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"}],accessData:"https://google.com. Accessed XXX 30, 2019."},{id:"017007",tab:"SED UT PERSPICIAZTIS",heading:"Unde omnis iste natus error",trialCode:"SED UT PERSPICIAZTIS",subheading:"Asit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.",phase:"2",status:"RENA",primaryEndpts:"Nemo enim ipsam",govId:"MNO56789012",contact:"Nemo enim ipsam (place@holder.com)",secondaryEndpts:"voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt",schematic:"outreach-007.svg",footnotes:["<sup>a</sup> Neque porro quisquam est, qui dolorem ipsum."],abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"CRS",definition:"cytokine release syndrome"},{name:"DHL",definition:"double-hit lymphoma"},{name:"DOR",definition:"duration of response"},{name:"DLBCL",definition:"diffuse large B-cell lymphoma"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"FL",definition:"follicular lymphoma"},{name:"HRQoL",definition:"health-related quality of life"},{name:"HSCT",definition:"hematopoietic stem cell transplant"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow-up"},{name:"NHL",definition:"non-Hodgkin lymphoma"},{name:"NOS",definition:"not otherwise specified"},{name:"NT",definition:"neurotoxicity"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PET",definition:"positron emission tomography"},{name:"PFS",definition:"progression-free survival"},{name:"PK",definition:"pharmacokinetics"},{name:"PMBCL",definition:"primary mediastinal large B-cell lymphoma"},{name:"R/R",definition:"relapsed/refractory"},{name:"tFL",definition:"transformed follicular lymphoma"},{name:"THL",definition:"triple-hit lymphoma"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"}],accessData:"https://clinicaltrials.gov/ct2/show/NCT03744676. Accessed Sep 30, 2019."},{id:"transform",tab:"CONSECTETUR",heading:"Quia dolor sit amet, consectetur, adipisci velit, sed quia",trialCode:"BFAX NVH-832 (CONSECTETUR)",subheading:"non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.",phase:"3",status:"CEMO",primaryEndpts:"NPF",govId:"PQR67890123",contact:"Ut enim ad minima veniam (place@holder.com)",secondaryEndpts:"quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur<sup>a</sup>",schematic:"transform.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"BEAM",definition:"a combination of chemotherapy drugs including BiCNU&copy; (carmustine), etoposide, Ara-C (cytarabine) and melphalan"},{name:"CR",definition:"complete response"},{name:"DLBCL",definition:"diffuse large B-cell lymphoma"},{name:"DHL",definition:"double-hit lymphoma"},{name:"DOR",definition:"duration of response"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"EFS",definition:"event-free survival"},{name:"FL",definition:"follicular lymphoma"},{name:"HRQoL",definition:"health-related quality of life"},{name:"HDCT",definition:"High dose chemotherapy"},{name:"HSCT",definition:"hematopoietic stem cell transplant"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow-up"},{name:"NOS",definition:"not otherwise specified"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PET",definition:"positron emission tomography"},{name:"PFS",definition:"progression-free survival"},{name:"PFS-2",definition:"progression after the next line of therapy"},{name:"PMBCL",definition:"primary mediastinal (thymic) large B-cell lymphoma"},{name:"R&#8209;DHAP",definition:"a combination of chemotherapy drugs including rituximab (Mabthera), dexamethasone, high-dose cytarabine (Ara-C) and cisplatin"},{name:"R-GDP",definition:"a combination of chemotherapy drugs including rituximab, gemcitabine, cisplatin, and dexamethasone"},{name:"R-ICE",definition:"a combination of chemotherapy drugs including rituximab, ifosfamide, carboplatin and etoposide"},{name:"R/R",definition:"relapsed/refractory"},{name:"tFL",definition:"transformed follicular lymphoma"},{name:"THL",definition:"triple-hit lymphoma"},{name:"THRBCL",definition:"T cell/histiocyte-rich large B-cell lymphoma"}],accessData:"https://clinicaltrials.gov/ct2/show/NCT03575351. Accessed Sep 30, 2019."},{id:"platform",tab:"Quis autem",heading:"Quis autem vel eum iure reprehenderit qui in ea voluptate",trialCode:"BCNF4534 (Quis autem)",subheading:"Avelit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur.",phase:"1/2",status:"POM",primaryEndpts:"Velit esse quam",govId:"PQR67891234",contact:"H. Rackham (place@holder.com)",secondaryEndpts:"Sed ut perspiciatis unde",schematic:"platform.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"DHL",definition:"double-hit lymphoma"},{name:"DLBCL",definition:"diffuse large B-cell lymphoma"},{name:"DLT",definition:"dose-limiting toxicity"},{name:"DOR",definition:"duration of response"},{name:"EBV",definition:"Epstein-Barr virus"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"EFS",definition:"event-free survival"},{name:"FL",definition:"follicular lymphoma"},{name:"HRQoL",definition:"health-related quality of life"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow-up"},{name:"NOS",definition:"not otherwise specified"},{name:"NHL",definition:"non-Hodgkin lymphoma"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PET",definition:"positron emission tomography"},{name:"PFS",definition:"progression-free survival"},{name:"PK",definition:"pharmacokinetics"},{name:"PMBCL",definition:"primary mediastinal (thymic) large B-cell lymphoma"},{name:"R/R",definition:"relapsed/refractory"},{name:"THL",definition:"triple-hit lymphoma"},{name:"T/HRLBCL",definition:"T cell/histiocyte-rich large B-cell nplymphoma"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"}],accessData:"https://google.com. Accessed XXX 30, 2019."},{id:"longtermfollow",tab:"Omnis iIte Natus",heading:"Perror sit voluptatem accusantium doloremque laudantium",trialCode:"FDS-75-JF",subheading:"A totam rem aperiam, eaque ipsa quae ab illo inventore veritatis.",phase:"2/3",status:"GUBI",primaryEndpts:"Et quasi architecto beatae vitae dicta sunt explicabo",govId:"BNV1234567",contact:"Cicero (place@holder.com)",secondaryEndpts:"N/A",schematic:"long-term-follow-up.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"HRQoL",definition:"health-related quality of life"},{name:"LTFU",definition:"long-term follow-up"},{name:"OS",definition:"overall survival"}],accessData:"https://clinicaltrials.gov/ct2/show/NCT03435796. Accessed Sep 30, 2019."}],references:{copyRefs:["Cicero. <em>commodi.</em> 2018 Jul 6."],videoRefs:{type:"video",columns:!0,left:["Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6."],leftIndex:5,right:["Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6.","Cicero. <em>commodi.</em> 2018 Jul 6."],rightIndex:15}}},"all-liso-cel":{buttonLabel:"Finibus Bonorum et Malorum",checkboxLabel:"Finibus Bonorum et Malorum",heading:"Finibus Bonorum et Malorum",subheading:"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque<sup>4</sup>",sidebarTitle:"Finibus",trials:[{id:"bcm004",tab:"Finibus",heading:"Safety and Efficacy of Liso-Cel in Pediatric Patients With R/R B-ALL and B-NHL",trialCode:"JCAR017-BCM-004",subheading:"A laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.",phase:"1b/2",status:"BNCE",primaryEndpts:"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit",govId:"BVN8765432",contact:"place@holder.com",secondaryEndpts:"Sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt",schematic:"bcm-004.svg",abbreviations:[{name:"B-ALL",definition:"B-cell acute lymphoblastic leukemia"},{name:"B-NHL",definition:"B-cell non-Hodgkin lymphoma"},{name:"CAR T",definition:"chimeric antigen receptor T-cell"},{name:"DLT",definition:"dose-limiting toxicity"},{name:"DOR",definition:"duration of response"},{name:"EFS",definition:"event-free survival"},{name:"HSCT",definition:"hematopoietic stem cell transplant"},{name:"LTFU",definition:"long-term follow-up"},{name:"MRD",definition:"minimal residual disease"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PK",definition:"pharmacokinetics"},{name:"R/R",definition:"relapsed/refractory"},{name:"RFS",definition:"relapse-free survival"},{name:"RP2D",definition:"recommended phase 2 dose"}]},{id:"longterm",tab:"Neque porro quisquam",heading:"Pest, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit",trialCode:"HF-764-OU",subheading:"Sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem",phase:"2/3",status:"NCJF",primaryEndpts:"Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur",govId:"BCHF12345678",contact:"place@holder.com",secondaryEndpts:"N/A",schematic:"long-term-follow-up.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"HRQoL",definition:"health-related quality of life"},{name:"LTFU",definition:"long-term follow-up"},{name:"OS",definition:"overall survival"}],accessData:"https://clinicaltrials.gov/ct2/show/NCT03435796. Accessed Jan 30, 2019."}],references:{copyRefs:{type:"copy",columns:!0,left:["H. Rackham. <em>Ovabule.</em> 2018 Jul 6.","H. Rackham. <em>Ovabule.</em> 2018 Jul 6.","H. Rackham. <em>Ovabule.</em> 2018 Jul 6.","H. Rackham. <em>Ovabule.</em> 2018 Jul 6.","H. Rackham. <em>Ovabule.</em> 2018 Jul 6."],right:["H. Rackham. <em>Ovabule.</em> 2018 Jul 6.","H. Rackham. <em>Ovabule.</em> 2018 Jul 6."],rightIndex:4}}},bb2121:{buttonLabel:"Quis autem vel eum iure reprehenderit qui",checkboxLabel:"Quis autem vel eum iure reprehenderit qui",heading:"Quis autem vel eum iure reprehenderit qui<sup>a</sup>",subheading:"An in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur<sup>1</sup>",sidebarTitle:"Quis autem",videos:[{id:"ch1",src:"video1.mp4",ref:"bb2121-1",title:"Quis autem",thumb:"thumbnail1.jpg"},{id:"ch2",src:"video2.mp4",ref:"bb2121-2",title:"At vero eos et accusamus",thumb:"thumbnail2.jpg"},{id:"ch3",src:"video3.mp4",ref:"bb2121-3",title:"Iet iusto odio dignissimos ducimus",thumb:"thumbnail3.jpg"},{id:"ch4",src:"video4.mp4",ref:"bb2121-4",title:"Qui blanditiis praesentium voluptatum deleniti",thumb:"thumbnail4.jpg"},{id:"ch5",src:"video5.mp4",ref:"bb2121-5",title:"Iatque corrupti quos dolores",thumb:"thumbnail5.jpg"}],trials:[{id:"karmma2",tab:"Molestias",heading:"Excepturi sint occaecati cupiditate",trialCode:"BCJ-43432",subheading:"A non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga.",phase:"2",status:"BURA",primaryEndpts:"Et harum quidem rerum facilis",govId:"Est et expedita distinctio",contact:"Est et expedita distinctio (place@holder.com)",secondaryEndpts:"Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime",schematic:"karmma-2.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"DEX",definition:"dexamethasone"},{name:"DOR",definition:"duration of response"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"HRQoL",definition:"health-related quality of life"},{name:"LEN",definition:"lenalidomide"},{name:"LTFU",definition:"long-term follow-up"},{name:"MM",definition:"multiple myeloma"},{name:"Mo",definition:"month"},{name:"MRD",definition:"minimal residual disease"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PD",definition:"progressive disease"},{name:"PI",definition:"proteasome inhibitor"},{name:"PK",definition:"pharmacokinetics"},{name:"PFS",definition:"progression-free survival"},{name:"PRO",definition:"patient-reported outcomes"},{name:"R/R",definition:"relapsed/refractory"},{name:"T<sub>last</sub>",definition:"time to last measurable CAR T cells."},{name:"T<sub>max</sub>",definition:"time to maximum concentration"},{name:"TTP",definition:"time to progression"},{name:"TTR",definition:"time to response"},{name:"VGPR",definition:"very good partial response"}],accessData:"https://google.com. Accessed XXX 29, 2019."},{id:"karmma3",tab:"Placeat",heading:"placeat facere possimus",trialCode:"NF-8765",subheading:"A omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.",phase:"3",status:"NBHY",primaryEndpts:"NJKHF",govId:"BCG45678",contact:"Necessitatibus (place@holder.com)",secondaryEndpts:"saepe eveniet ut et voluptates repudiandae sint et molestiae",schematic:"karmma-3.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"maximum concentration"},{name:"CR",definition:"complete response"},{name:"DARA",definition:"daratumumab"},{name:"DOR",definition:"duration of response"},{name:"DPd",definition:"daratumumab in combination with pomalidomide and low-dose dexamethasone"},{name:"DVd",definition:"daratumumab in combination with bortezomib and low-dose dexamethasone"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"EFS",definition:"event-free survival"},{name:"HRQoL",definition:"health-related quality of life"},{name:"IRd",definition:"ixazomib in combination with lenalidomide and low-dose dexamethasone"},{name:"LTFU",definition:"long-term follow-up"},{name:"MM",definition:"multiple myeloma"},{name:"Mo",definition:"month"},{name:"MRD",definition:"minimal residual disease"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PI",definition:"proteasome inhibitor"},{name:"PK",definition:"pharmacokinetics"},{name:"PFS",definition:"progression-free survival"},{name:"PFS2",definition:"progression-free survival after next-line therapy"},{name:"PRO",definition:"patient-reported outcomes"},{name:"R/R",definition:"relapsed/refractory"},{name:"T<sub>last</sub>",definition:"time to last measurable CAR T cells."},{name:"T<sub>max</sub>",definition:"time to maximum concentration"},{name:"TTR",definition:"time to response"}],accessData:"https://google.com. Accessed XXX 29, 2019."},{id:"longterm",tab:"Lonon Recusandae",heading:"Itaque earum rerum hic tenetur a sapiente delectus",trialCode:"GT-876",subheading:"A ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat.",phase:"2/3",status:"NVHY",primaryEndpts:"ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat.",govId:"BFJD345678",contact:"place@holder.com",secondaryEndpts:"N/A",schematic:"long-term-follow-up.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"HRQoL",definition:"health-related quality of life"},{name:"LTFU",definition:"long-term follow up"},{name:"OS",definition:"overall survival"}],accessData:"https://google.com. Accessed XXX 18, 2019."}],references:{copyRefs:["Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017."],videoRefs:{type:"video",columns:!0,left:["Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017."],leftIndex:4,right:["Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017.","Lorem I. <em>Resapiente.</em> 2017."],rightIndex:15}}},bb21217:{buttonLabel:"Delectus",checkboxLabel:"Delectus",heading:"Delectus<sup>a</sup>",subheading:"A ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat.<sup>3</sup>",sidebarTitle:"Delectus",trials:[{id:"crb402",tab:"DJG-865",heading:"Lorem ipsum dolor sit amet",trialCode:"DJG-865",subheading:"consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.",phase:"1",status:"BURT",primaryEndpts:"Ut enim ad minim veniam, quis nostrud exercitation",govId:"CHF45678",contact:"Ut enim ad minim veniam (place@holder.com)",secondaryEndpts:"Ut enim ad minim veniam, quis nostrud exercitation",schematic:"crb-402.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"CR",definition:"complete response"},{name:"DLT",definition:"dose-limiting toxicity"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"IMWG",definition:"International Myeloma Working Group"},{name:"LTFU",definition:"long-term follow-up"},{name:"MM",definition:"multiple myeloma"},{name:"PI",definition:"proteasome inhibitor"},{name:"PR",definition:"partial response"},{name:"R/R",definition:"relapsed/refractory"},{name:"VGPR",definition:"very good partial response"}],accessData:"https://google.com. Accessed XXX 28, 2019."}],references:{copyRefs:["Dolor SIt. https://www.google.com. Accessed XXX 29, 2019.","Dolor SIt. https://www.google.com. Accessed XXX 29, 2019.","Dolor SIt. https://www.google.com. Accessed XXX 29, 2019."],videoRefs:[]}},jcarh125:{buttonLabel:"Oullamco laboris nisi ut aliquip",checkboxLabel:"Oullamco laboris nisi ut aliquip",heading:"Oullamco laboris nisi ut aliquip",subheading:"An ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.<sup>3</sup>",sidebarTitle:"Oullamco",trials:[{id:"evolve",tab:"Oullamco",heading:"Excepteur sint occaecat cupidatat",trialCode:"Excepteur",subheading:"An non proident, sunt in culpa qui officia.",phase:"1/2",status:"NFHJE",primaryEndpts:"deserunt mollit anim id est laborum",govId:"BFJ345678",contact:"Deserunt mollit anim id est laborum (place@holder.com)",secondaryEndpts:"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto",schematic:"evolve.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"ASCT",definition:"autologous stem cell transplant"},{name:"AUC",definition:"area under the curve"},{name:"C<sub>max</sub>",definition:"complete response"},{name:"CR",definition:"complete response"},{name:"DLT",definition:"dose-limiting toxicity"},{name:"ECOG PS",definition:"Eastern Cooperative Oncology Group performance status"},{name:"HRQoL",definition:"health-related quality of life"},{name:"IV",definition:"intravenous"},{name:"LTFU",definition:"long-term follow up"},{name:"MM",definition:"multiple myeloma"},{name:"ORR",definition:"overall response rate"},{name:"OS",definition:"overall survival"},{name:"PFS",definition:"progression-free survival"},{name:"PI",definition:"proteasome inhibitor"},{name:"PK",definition:"pharmacokinetics"},{name:"R/R",definition:"relapsed/refractory"},{name:"T<sub>max</sub>",definition:"time to maximum concentration"}],accessData:"https://clinicaltrials.gov/ct2/show/NCT03274219. Accessed July 18, 2019."},{id:"longterm",tab:"Beatae vitae dicta sunt explicabo",heading:"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit",trialCode:"BF-KFHD-02",subheading:"Sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt.",phase:"2/3",status:"BFUJE",primaryEndpts:"Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet",govId:"BFJ67890",contact:"place@holder.com",secondaryEndpts:"N/A",schematic:"long-term-follow-up.svg",abbreviations:[{name:"AE",definition:"adverse event"},{name:"HRQoL",definition:"health-related quality of life"},{name:"LTFU",definition:"long-term follow up"},{name:"OS",definition:"overall survival"}],accessData:"https://google.com. Accessed XXX 18, 2019."}],references:{copyRefs:["Finibus Bonorum et Malorum. https://www.google.com. Accessed XXX 29, 2019.","Finibus Bonorum et Malorum. https://www.google.com. Accessed XXX 29, 2019.","Finibus Bonorum et Malorum. https://www.google.com. Accessed XXX 29, 2019."]}}}}},c3c1:function(e,i,n){"use strict";var a=function(){var e=this,i=e.$createElement,n=e._self._c||i;return n("div",{staticClass:"project-code"},[n("p",{staticClass:"date"},[e._v("\n    © 2019 Company Corporation"),e.$route.params.id?e._e():n("br"),e._v("\n    10/19\n  ")])])},t=[],o=(n("49d2"),n("2877")),m={},s=Object(o["a"])(m,a,t,!1,null,"2b0efdbe",null);i["a"]=s.exports}}]);
//# sourceMappingURL=chunk-dca937f8.089586ee.js.map